Erasca is a clinical-stage precision oncology company dedicated to discovering and developing medicines that target the RAS/MAPK pathway, a key driver of cancer in millions of patients worldwide. Our innovative approach aims to create effective treatments that directly address one of the most prevalent mutations in cancer, enhancing the lives of those affected.
